Aims The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs)
associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown …

Simple Summary This review article addresses the toxic effects on the heart associated with
the use of certain cancer-treating drugs known as immune checkpoint inhibitors. These …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

Immunotherapy sheds new light to cancer treatment and is satisfied by cancer patients.
However, immunotoxicity, single‐source antibodies, and single‐targeting stratege are …

As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of
the potential adverse effects of these drugs continues to broaden. Emerging evidence …

АВ—атриовентрикулярный (ая) АГ—артериальная гипертензия АД—артериальное
давление АТ—артериальный тромбоз АТО—атеротромботические осложнения АТФ …

PURPOSE In rare cases, immune checkpoint inhibitors (ICIs) cause immune-mediated
myocarditis. However, true incidence of other major adverse cardiovascular events (MACEs) …

Background and Purpose Immune checkpoint inhibitors (ICI), such as anti‐PD‐1
monoclonal antibodies, have revolutionized cancer therapy by enhancing the cytotoxic …

Immunotherapy revolutionised oncology by harnessing the native immune system to
effectively treat a wide variety of malignancies even at advanced stages. Off-target immune …